JP2017524719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524719A5 JP2017524719A5 JP2017507823A JP2017507823A JP2017524719A5 JP 2017524719 A5 JP2017524719 A5 JP 2017524719A5 JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017524719 A5 JP2017524719 A5 JP 2017524719A5
- Authority
- JP
- Japan
- Prior art keywords
- esketamine
- patient
- depression
- pharmaceutical composition
- dosing regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036896P | 2014-08-13 | 2014-08-13 | |
| US62/036,896 | 2014-08-13 | ||
| PCT/US2015/044830 WO2016025581A1 (en) | 2014-08-13 | 2015-08-12 | Method for the treatment of depression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524719A JP2017524719A (ja) | 2017-08-31 |
| JP2017524719A5 true JP2017524719A5 (2) | 2018-09-20 |
| JP6545788B2 JP6545788B2 (ja) | 2019-07-17 |
Family
ID=55301311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507823A Active JP6545788B2 (ja) | 2014-08-13 | 2015-08-12 | うつ病の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10098854B2 (2) |
| EP (1) | EP3179993B1 (2) |
| JP (1) | JP6545788B2 (2) |
| KR (1) | KR20170040800A (2) |
| CN (1) | CN106714789A (2) |
| AU (2) | AU2015301782B2 (2) |
| CA (1) | CA2957926A1 (2) |
| IL (2) | IL250490A0 (2) |
| MA (1) | MA40462A (2) |
| MX (1) | MX2017001908A (2) |
| WO (1) | WO2016025581A1 (2) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| EP3094312B1 (en) * | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| WO2019094757A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| KR20240011237A (ko) * | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| EP3915120A1 (en) * | 2019-01-23 | 2021-12-01 | The Regents of the University of Michigan | Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors |
| JP2022524008A (ja) | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| US20210407643A1 (en) * | 2020-06-25 | 2021-12-30 | Greenway Dna Inc. | Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| JP7846211B2 (ja) | 2021-08-19 | 2026-04-14 | デフィニウム セラピューティクス ユーエス， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| RU2224523C2 (ru) | 1998-07-24 | 2004-02-27 | Сео Хонг Ю | Водный раствор, содержащий желчную кислоту, и способ его получения |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| CA2529857A1 (en) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| AU2007229866A1 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20090306137A1 (en) | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| EP2992877A1 (en) | 2010-06-15 | 2016-03-09 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| RU2622082C2 (ru) | 2011-11-14 | 2017-06-09 | Нестек С.А. | Анализы и способы выбора режима лечения пациента с депрессией |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| KR20150096370A (ko) | 2012-08-23 | 2015-08-24 | 스튜어트 엘. 웨그 | 항불안제 조성물, 제형 및 사용방법 |
| DK2983787T3 (da) | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2015
- 2015-08-12 KR KR1020177006277A patent/KR20170040800A/ko not_active Ceased
- 2015-08-12 EP EP15831762.8A patent/EP3179993B1/en active Active
- 2015-08-12 WO PCT/US2015/044830 patent/WO2016025581A1/en not_active Ceased
- 2015-08-12 CA CA2957926A patent/CA2957926A1/en not_active Abandoned
- 2015-08-12 MX MX2017001908A patent/MX2017001908A/es unknown
- 2015-08-12 MA MA040462A patent/MA40462A/fr unknown
- 2015-08-12 US US14/824,513 patent/US10098854B2/en active Active
- 2015-08-12 CN CN201580043454.XA patent/CN106714789A/zh active Pending
- 2015-08-12 JP JP2017507823A patent/JP6545788B2/ja active Active
- 2015-08-12 AU AU2015301782A patent/AU2015301782B2/en not_active Ceased
-
2017
- 2017-02-07 IL IL250490A patent/IL250490A0/en active IP Right Grant
-
2020
- 2020-12-03 AU AU2020281101A patent/AU2020281101A1/en not_active Abandoned
- 2020-12-21 IL IL279627A patent/IL279627A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524719A5 (2) | ||
| JP2017528483A5 (2) | ||
| JP7832987B2 (ja) | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム | |
| Montgomery et al. | A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine | |
| Farlow et al. | Pharmacologic treatment of cognition in Alzheimer's dementia | |
| Apud et al. | Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia | |
| Malhi et al. | Pharmacological management of unipolar depression | |
| MX2017001908A (es) | Metodo para el tratamiento de la depresion. | |
| JP2009215293A5 (2) | ||
| JP2017511377A5 (2) | ||
| JP2015504871A5 (2) | ||
| JP2017501848A5 (2) | ||
| JP2014502641A5 (2) | ||
| HRP20251310T1 (hr) | Enzimsko-nadomjesna terapija s povezivanjem doze za liječenje deficita kisele sfingomijelinaze | |
| JP2016506933A5 (2) | ||
| JP2015505564A5 (2) | ||
| JP2020533381A5 (2) | ||
| JP2017533220A5 (2) | ||
| O'Donovan et al. | Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression | |
| JP2017514853A5 (2) | ||
| JP2016512817A5 (2) | ||
| JP2016510343A5 (2) | ||
| JP2015522603A5 (2) | ||
| Elazar et al. | Emerging concepts for the treatment of hepatitis delta | |
| Shelton | What are the comparative benefits and harms of augmentation treatments in major depression |